Representative Image
BEIJING: Chinese COVID-19 vaccine candidate, CoronaVac, developed by Sinovac Biotech, triggered quick immune response in its late stage trails. However, the level of antibodies produced was lower than the people who already had COVID-19 before and had recovered. The researchers said that CoronaVac can provide sufficient protection from novel coronavirus infection based on their experience with other vaccines and preclinical trails.
CoronaVac and other Chinese vaccines are going through late stage trails to determine their effectiveness on COVID-19. Zhu Fegcai, one of the authors, said that the findings show that CoronaVac is capable of inducing a quick antibody response within four weeks of immunisation with two doses at an interval of 14 days.
Researchers said that the large last-stage trails will be important to determine the immune response generated by the CoronaVac vaccine. Sinovac vaccine is also in the Phase 3 trails in Indonesia, Brazil and Turkey.
Representative Image NEW DELHI: Nitin Gadkari, Minister for Road Transport and Highways, Government of India,…
Representative Image GANDHINAGAR, Gujarat: Gujarat has reached a significant milestone in the construction of homes…
Representative Image THANE, Maharashtra: The Mira Bhayander Municipal Corporation (MBMC) in Maharashtra has established a…
Representative Image NEW DELHI: With the aim to tackle the increasing air pollution level in…
Representative Image LUCKNOW, Uttar Pradesh: The Uttar Pradesh State Industrial Development Authority (UPSIDA) has come…
Representative Image NEW DELHI: The Delhi Jal Board (DJB) plans to collaborate with the Water…